It was reported that IL-6 contributed to the conversion of prostate cancer to an androgen-independent state in xenografts models [8,28], and anti-IL-6 monoclonal antibody have been applied to treat metastatic castration-resistant prostate cancer in clinical studies [29]. This evidence concerns the gene IL6 and prostate carcinoma.